{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:23:09Z","timestamp":1777537389888,"version":"3.51.4"},"reference-count":115,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.xcrm.2024.101702","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T18:52:47Z","timestamp":1725043967000},"page":"101702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines"],"prefix":"10.1016","volume":"5","author":[{"given":"Magdalena","family":"Schwarzm\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merle","family":"Schanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene A.","family":"Abela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvan","family":"Grosse-Holz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina","family":"Epp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Curcio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jule","family":"Greshake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Rusert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger D.","family":"Kouyos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huldrych F.","family":"G\u00fcnthard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1013-876X","authenticated-orcid":false,"given":"Alexandra","family":"Trkola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101702_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ije\/dyab141","article-title":"Cohort Profile Update: The Swiss HIV Cohort Study (SHCS)","volume":"51","author":"Scherrer","year":"2022","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.xcrm.2024.101702_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2024.101702_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.it.2010.12.002","article-title":"Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus","volume":"32","author":"Guihot","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xcrm.2024.101702_bib4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1056\/NEJMoa1110187","article-title":"Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy","volume":"368","author":"Le","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.qai.0000233310.90484.16","article-title":"Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study","volume":"43","author":"Palella","year":"2006","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.xcrm.2024.101702_bib6","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archinte.165.4.416","article-title":"The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy","volume":"165","author":"d'Arminio Monforte","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/QAD.0b013e3283324283","article-title":"The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals","volume":"24","author":"Ray","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.xcrm.2024.101702_bib8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/QAD.0000000000001335","article-title":"Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population","volume":"31","author":"Gueler","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.xcrm.2024.101702_bib9","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/QAD.0000000000000243","article-title":"Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy","volume":"28","author":"May","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.xcrm.2024.101702_bib10","doi-asserted-by":"crossref","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2024.101702_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib12","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib13","doi-asserted-by":"crossref","first-page":"e27047","DOI":"10.1371\/journal.pone.0027047","article-title":"Optimal antiviral switching to minimize resistance risk in HIV therapy","volume":"6","author":"Luo","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2024.101702_bib14","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1086\/343050","article-title":"Switching effective antiretroviral therapy: a review","volume":"35","author":"Drechsler","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101702_bib15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.xcrm.2024.101702_bib16","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/jac\/dkx068","article-title":"Evolution of blood-associated HIV-1 DNA levels after 48\u00a0weeks of switching to atazanavir\/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial","volume":"72","author":"Lombardi","year":"2017","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.xcrm.2024.101702_bib17","doi-asserted-by":"crossref","first-page":"ofac107","DOI":"10.1093\/ofid\/ofac107","article-title":"Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials","volume":"9","author":"Fournier","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101702_bib18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/ciy1131","article-title":"Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial","volume":"69","author":"Braun","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101702_bib19","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/cid\/ciad366","volume":"77","author":"West","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101702_bib20","first-page":"44","article-title":"Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection","volume":"40","author":"Truong","year":"2015","journal-title":"P T."},{"key":"10.1016\/j.xcrm.2024.101702_bib21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkab324","article-title":"Long-acting antiretrovirals: a new era for the management and prevention of HIV infection","volume":"77","author":"Thoueille","year":"2022","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.xcrm.2024.101702_bib22","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib23","doi-asserted-by":"crossref","first-page":"eaaz2686","DOI":"10.1126\/scitranslmed.aaz2686","article-title":"Multiple roles for HIV broadly neutralizing antibodies","volume":"11","author":"Haynes","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COH.0000000000000600","article-title":"Broadly neutralizing antibodies for the treatment and prevention of HIV infection","volume":"15","author":"Caskey","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.xcrm.2024.101702_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11904-016-0299-7","article-title":"Broadly Neutralizing Antibodies for HIV Eradication","volume":"13","author":"Stephenson","year":"2016","journal-title":"Curr. HIV AIDS Rep."},{"key":"10.1016\/j.xcrm.2024.101702_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2015.05.001","article-title":"HIV therapeutic vaccines: moving towards a functional cure","volume":"35","author":"Mylvaganam","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xcrm.2024.101702_bib27","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(21)00570-5","article-title":"Eliminating postnatal HIV transmission in high incidence areas: need for complementary biomedical interventions","volume":"397","author":"Van de Perre","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101702_bib28","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S1473-3099(23)00481-4","article-title":"Vaccinating people living with HIV: a fast track to preventive and therapeutic HIV vaccines","volume":"24","author":"Trkola","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101702_bib29","doi-asserted-by":"crossref","first-page":"89S","DOI":"10.1111\/j.1365-2125.2001.00380.x","article-title":"The role of therapeutic drug monitoring in treatment of HIV infection","volume":"52","author":"Back","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.xcrm.2024.101702_bib30","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1084\/jem.20190446","article-title":"Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses","volume":"216","author":"Dosenovic","year":"2019","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib31","first-page":"12.11.1","article-title":"Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol Chapter","volume":"Chapter 12","author":"Montefiori","year":"2005","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.xcrm.2024.101702_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.xcrm.2024.101702_bib33","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1016\/S2352-3018(23)00003-6","article-title":"Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial","volume":"10","author":"Mahomed","year":"2023","journal-title":"Lancet. HIV"},{"key":"10.1016\/j.xcrm.2024.101702_bib34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib35","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","author":"Gaebler","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101702_bib36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virol.2006.11.004","article-title":"HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry","volume":"361","author":"Pugach","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2024.101702_bib37","first-page":"559","article-title":"2022 update of the drug resistance mutations in HIV-1","volume":"30","author":"Wensing","year":"2023","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.xcrm.2024.101702_bib38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.virusres.2007.12.021","article-title":"HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex\u00a0vivo","volume":"134","author":"Martinez-Picado","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.xcrm.2024.101702_bib39","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1128\/JCM.43.3.1395-1400.2005","article-title":"Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation","volume":"43","author":"Weber","year":"2005","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.xcrm.2024.101702_bib40","first-page":"979","article-title":"Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1","volume":"10","author":"Turner","year":"2003","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.xcrm.2024.101702_bib41","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/AAC.02568-12","article-title":"Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness","volume":"57","author":"Abram","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.xcrm.2024.101702_bib42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1128\/AAC.38.2.275","article-title":"Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine","volume":"38","author":"Gu","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.xcrm.2024.101702_bib43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2217\/hiv.09.40","article-title":"The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications","volume":"3","author":"Brenner","year":"2009","journal-title":"HIV Ther."},{"key":"10.1016\/j.xcrm.2024.101702_bib44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1586\/14787210.2.1.147","article-title":"The impact of the M184V substitution on drug resistance and viral fitness","volume":"2","author":"Wainberg","year":"2004","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.xcrm.2024.101702_bib45","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.04215-14","article-title":"Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors","volume":"59","author":"Basson","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.xcrm.2024.101702_bib46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/QCO.0b013e32835ba81c","article-title":"Evolution of HIV integrase resistance mutations","volume":"26","author":"Quashie","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101702_bib47","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3390\/v2071347","article-title":"Resistance to integrase inhibitors","volume":"2","author":"Metifiot","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.xcrm.2024.101702_bib48","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/JVI.06591-11","article-title":"Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir","volume":"86","author":"Quashie","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101702_bib49","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.virol.2010.03.034","article-title":"Primary mutations selected in\u00a0vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles","volume":"402","author":"Goethals","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2024.101702_bib50","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.00470-08","article-title":"Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors","volume":"82","author":"Goethals","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101702_bib51","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12977-018-0440-3","article-title":"Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir","volume":"15","author":"Oliveira","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.xcrm.2024.101702_bib52","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib53","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00003495-199856060-00014","article-title":"Efavirenz","volume":"56","author":"Adkins","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2024.101702_bib54","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/jac\/dkp334","article-title":"Efavirenz: a decade of clinical experience in the treatment of HIV","volume":"64","author":"Maggiolo","year":"2009","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.xcrm.2024.101702_bib55","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1086\/498348","article-title":"Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus","volume":"42","author":"Saag","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.xcrm.2024.101702_bib56","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2165\/00003495-200363220-00003","article-title":"Emtricitabine: an antiretroviral agent for HIV infection","volume":"63","author":"Bang","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2024.101702_bib57","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.2147\/DDDT.S84850","article-title":"Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV","volume":"9","author":"Kandel","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.xcrm.2024.101702_bib58","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1517\/13543784.2012.661713","article-title":"Dolutegravir for the treatment of HIV","volume":"21","author":"Katlama","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.xcrm.2024.101702_bib59","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1016\/j.bmc.2007.09.010","article-title":"Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV","volume":"15","author":"Ghosh","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.xcrm.2024.101702_bib60","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40265-013-0159-3","article-title":"Darunavir: a review of its use in the management of HIV-1 infection","volume":"74","author":"Deeks","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2024.101702_bib61","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101702_bib62","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FTD.0b013e31821b42d1","article-title":"The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection","volume":"33","author":"Pretorius","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.xcrm.2024.101702_bib63","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jac\/dkv425","article-title":"Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake","volume":"71","author":"Elliot","year":"2016","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.xcrm.2024.101702_bib64","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3851\/IMP3119","article-title":"Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?","volume":"22","author":"Cattaneo","year":"2017","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.xcrm.2024.101702_bib65","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance","volume":"74","author":"Rhee","year":"2019","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.xcrm.2024.101702_bib66","doi-asserted-by":"crossref","first-page":"e1963","DOI":"10.1002\/rmv.1963","article-title":"Current status on the development of pseudoviruses for enveloped viruses","volume":"28","author":"Li","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.xcrm.2024.101702_bib67","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1038\/s41596-020-0394-5","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay","volume":"15","author":"Nie","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.xcrm.2024.101702_bib68","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1099\/vir.0.065201-0","article-title":"Pseudotyping of vesicular stomatitis virus with the envelope glycoproteins of highly pathogenic avian influenza viruses","volume":"95","author":"Zimmer","year":"2014","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.xcrm.2024.101702_bib69","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/978-1-59745-181-9_23","article-title":"Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins","volume":"454","author":"Fukushi","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2024.101702_bib70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.virol.2015.11.002","article-title":"Characterization of the glycoproteins of bat-derived influenza viruses","volume":"488","author":"Maruyama","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2024.101702_bib71","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1006\/viro.1998.9429","article-title":"A plasma membrane localization signal in the HIV-1 envelope cytoplasmic domain prevents localization at sites of vesicular stomatitis virus budding and incorporation into VSV virions","volume":"251","author":"Johnson","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2024.101702_bib72","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1128\/JVI.75.5.2337-2344.2001","article-title":"Mutations in the cytoplasmic tail of murine leukemia virus envelope protein suppress fusion inhibition by R peptide","volume":"75","author":"Li","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101702_bib73","doi-asserted-by":"crossref","first-page":"8490","DOI":"10.1128\/jvi.71.11.8490-8496.1997","article-title":"Analysis of the murine leukemia virus R peptide: delineation of the molecular determinants which are important for its fusion inhibition activity","volume":"71","author":"Yang","year":"1997","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101702_bib74","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.1128\/JVI.00230-12","article-title":"Neutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tail","volume":"86","author":"Durham","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101702_bib75","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1126\/science.aaa9804","article-title":"Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein","volume":"349","author":"Chen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101702_bib76","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12977-018-0431-4","article-title":"Cell surface ectodomain integrity of a subset of functional HIV-1 envelopes is dependent on a conserved hydrophilic domain containing region in their C-terminal tail","volume":"15","author":"Samal","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.xcrm.2024.101702_bib77","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1128\/JVI.02482-10","article-title":"Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia","volume":"85","author":"Medina-Ramirez","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101702_bib78","doi-asserted-by":"crossref","first-page":"e20212045","DOI":"10.1084\/jem.20212045","article-title":"Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller","volume":"219","author":"Lorin","year":"2022","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib79","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s10875-014-0010-y","article-title":"Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy","volume":"34","author":"Andrabi","year":"2014","journal-title":"J.\u00a0Clin. Immunol."},{"key":"10.1016\/j.xcrm.2024.101702_bib80","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib81","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1089\/088922203769232629","article-title":"Protein binding in antiretroviral therapies","volume":"19","author":"Boffito","year":"2003","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.xcrm.2024.101702_bib82","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0301-4622(03)00071-1","article-title":"The binding of HIV-1 protease inhibitors to human serum proteins","volume":"105","author":"Schon","year":"2003","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.xcrm.2024.101702_bib83","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dki308","article-title":"Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals","volume":"56","author":"Almond","year":"2005","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.xcrm.2024.101702_bib84","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00007691-200502000-00014","article-title":"The pH dependency of the binding of drugs to plasma proteins in man","volume":"27","author":"Hinderling","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.xcrm.2024.101702_bib85","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3390\/microorganisms12020302","article-title":"Cohort Profile: The Zurich Primary HIV Infection Study","volume":"12","author":"Freind","year":"2024","journal-title":"Microorganisms"},{"key":"10.1016\/j.xcrm.2024.101702_bib86","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/nm.4187","article-title":"Determinants of HIV-1 broadly neutralizing antibody induction","volume":"22","author":"Rusert","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib87","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1084\/jem.20180246","article-title":"Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity","volume":"215","author":"Kadelka","year":"2018","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib88","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib89","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101702_bib90","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","article-title":"Combination anti-HIV antibodies provide sustained virological suppression","volume":"606","author":"Sneller","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101702_bib91","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.virol.2005.11.032","article-title":"Mutations at the C-terminus of the simian immunodeficiency virus envelope glycoprotein affect gp120-gp41 stability on virions","volume":"347","author":"Affranchino","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.xcrm.2024.101702_bib92","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1128\/JVI.76.6.2683-2691.2002","article-title":"Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein","volume":"76","author":"Edwards","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101702_bib93","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1128\/JVI.79.1.106-115.2005","article-title":"The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle","volume":"79","author":"Abrahamyan","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.xcrm.2024.101702_bib94","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1073\/pnas.0800255105","article-title":"A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies","volume":"105","author":"Frey","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101702_bib95","doi-asserted-by":"crossref","first-page":"20234","DOI":"10.1073\/pnas.0908713106","article-title":"Role of HIV membrane in neutralization by two broadly neutralizing antibodies","volume":"106","author":"Alam","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101702_bib96","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1038\/s41591-023-02582-3","article-title":"Dynamics and durability of HIV-1 neutralization are determined by viral replication","volume":"29","author":"Schommers","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib97","doi-asserted-by":"crossref","first-page":"e85371","DOI":"10.1371\/journal.pone.0085371","article-title":"HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study","volume":"9","author":"Gach","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2024.101702_bib98","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJM197602052940605","article-title":"Binding of drugs to serum albumin (first of two parts)","volume":"294","author":"Koch-Weser","year":"1976","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib99","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0167-4838(00)00153-9","article-title":"Alpha-1-acid glycoprotein","volume":"1482","author":"Fournier","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.xcrm.2024.101702_bib100","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2165\/00003088-197803020-00004","article-title":"Diseases and drug protein binding","volume":"3","author":"Tillement","year":"1978","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.xcrm.2024.101702_bib101","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/clpt.1984.51","article-title":"Alpha 1-acid glycoprotein and albumin in human serum bupivacaine binding","volume":"35","author":"Denson","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2024.101702_bib102","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1042\/bj2890767","article-title":"pH-dependence of warfarin binding to alpha 1-acid glycoprotein (orosomucoid)","volume":"289","author":"Urien","year":"1993","journal-title":"Biochem. J."},{"key":"10.1016\/j.xcrm.2024.101702_bib103","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1039\/b808938h","article-title":"About the albumin structure in solution: cigar Expanded form versus heart Normal shape","volume":"10","author":"Leggio","year":"2008","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.xcrm.2024.101702_bib104","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0021-9258(18)67930-X","article-title":"A structural transformation in bovine and human plasma albumins in alkaline solution as revealed by rotatory dispersion studies","volume":"238","author":"Leonard","year":"1963","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2024.101702_bib105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0167-4838(82)90467-8","article-title":"The effects of N-B transition of\u00a0human serum albumin on the specific drug-binding sites","volume":"709","author":"Wanwimolruk","year":"1982","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.xcrm.2024.101702_bib106","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10238-018-0523-4","article-title":"Establishment and evaluation of a general dissociation technique for antibodies in circulating immune complexes","volume":"19","author":"Wang","year":"2019","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib107","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1128\/jcm.31.6.1656-1658.1993","article-title":"Increased detection of human immunodeficiency virus antigenemia after dissociation of immune complexes at low pH","volume":"31","author":"Pokriefka","year":"1993","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.xcrm.2024.101702_bib108","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM199302043280501","article-title":"Rapid serologic testing with immune-complex-dissociated HIV p24 antigen for early detection of\u00a0HIV infection in neonates. Southern California Pediatric AIDS Consortium","volume":"328","author":"Miles","year":"1993","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101702_bib109","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ije\/dyp321","article-title":"Cohort profile: the Swiss HIV Cohort study","volume":"39","author":"Schoeni-Affolter","year":"2010","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.xcrm.2024.101702_bib110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jviromet.2016.11.008","article-title":"MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing","volume":"240","author":"Huber","year":"2017","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.xcrm.2024.101702_bib111","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.xcrm.2024.101702_bib112","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","article-title":"Generation of VSV pseudotypes using recombinant DeltaG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines","volume":"169","author":"Whitt","year":"2010","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.xcrm.2024.101702_bib113","first-page":"1","article-title":"Fitting Linear Mixed-Effects Models Using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J.\u00a0Stat. Software"},{"key":"10.1016\/j.xcrm.2024.101702_bib114","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.xcrm.2024.101702_bib115","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124004233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124004233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T17:08:31Z","timestamp":1727284111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124004233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":115,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2666379124004233"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101702","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.xpro.2024.103056","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101702"}}